Cognizant (CTSH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Cognizant (CTSH) reported strong Q2 2025 results, with revenue of $5.25 billion, up 8.1% year-over-year and beating the $5.19 billion consensus by 1.01%. Diluted EPS reached $1.31, exceeding the $1.26 estimate by 3.97%. While overall results surpassed expectations, segment performance was mixed, with Health Sciences revenue falling short of estimates, though other key segments like Products and Resources and Financial Services exceeded. Despite these beats, CTSH shares have underperformed, declining 6.9% over the past month compared to the S&P 500's 3.4% gain.

Analysis

Cognizant (CTSH) delivered a solid second-quarter 2025 performance, with revenue of $5.25 billion and EPS of $1.31 surpassing Wall Street consensus estimates by 1.01% and 3.97%, respectively. The top-line growth of 8.1% year-over-year was driven by notable strength in the Products and Resources segment, which expanded by a robust 16% and beat analyst projections. The Financial Services and Communications, Media and Technology segments also exceeded their revenue estimates with respective year-over-year growth of 6.9% and 3.1%. However, this positive performance was partially offset by a significant miss in the Health Sciences division, which reported $1.55 billion in revenue against an estimated $1.61 billion. This mixed internal performance is mirrored by the stock's market activity, which saw a -6.9% return over the past month, starkly underperforming the S&P 500 composite's +3.4% gain and suggesting that the headline earnings beat may not be enough to assuage investor concerns.

Key Decisions for Investors

• Investors should look beyond the headline revenue and EPS beats and scrutinize the mixed performance across business segments, particularly the notable revenue miss in the Health Sciences division.
• The stock's significant underperformance of -6.9% in the past month, despite the positive earnings report, warrants caution and suggests the market may be weighing the segment-level weakness more heavily than the overall growth.
• Monitor the performance of the Products and Resources segment, whose 16% growth was a key driver this quarter, to see if its strength can continue to offset potential sluggishness in other areas like Health Sciences.
• The current Zacks Rank #3 (Hold) aligns with the conflicting data, suggesting a neutral stance may be prudent until there is more clarity on the trajectory of the underperforming segments.